Daniel Checketts

2.8k citations

29 papers · 1.7k indexed · 2 hit papers · h-index 17

Impact in

Pharmacology top 0.5%
- Cannabis and Cannabinoid Research
Psychiatry and Mental health top 1%
- Epilepsy research and treatment

Papers in ⓘ

Pharmacology 21
- Cannabis and Cannabinoid Research 21
Psychiatry and Mental health 17
- Epilepsy research and treatment 15

Co-authors: Orrin Devinsky (9 shared papers)Anup D. Patel (5 shared papers)Claire Roberts (3 shared papers)Vicente Villanueva (5 shared papers)Michael Privitera (4 shared papers)Elaine Wirrell (2 shared papers)Kevan VanLandingham (5 shared papers)J. Helen Cross (2 shared papers)
Journals: Epilepsia (9 papers)Neurology (7 papers)Multiple Sclerosis and Related Disorders (2 papers)Acta Neurologica Scandinavica (2 papers)Epilepsy & Behavior (1 paper)
Partner nations: United Kingdom United States Spain

In The Last Decade

Daniel Checketts

28 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome 2020 · 192 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 JAMA Neurology
2018 New England Journal of Medicine

Peers

Countries citing papers authored by Daniel Checketts

Since Specialization

Citations

This map shows the geographic impact of Daniel Checketts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Checketts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Checketts more than expected).

Fields of papers citing papers by Daniel Checketts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Checketts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Checketts. The network helps show where Daniel Checketts may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Checketts, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Checketts Line = papers co-authored together Daniel Checketts links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome New England Journal of Medicine ·Orrin Devinsky, Anup D. Patel, J. Helen Cross, Vicente Villanueva, Elaine Wirrell, Michael Privitera, Sam M. Greenwood, Claire Roberts, Daniel Checketts, Kevan VanLandingham, Sameer M. Zuberi Hit paper breakdown →	2018	661
2	Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome JAMA Neurology ·Ian Miller, Ingrid E. Scheffer, Boudewijn Gunning, Rocío Sánchez‐Carpintero, António Gil‐Nagel, Μ. Scott Perry, Russell P. Saneto, Daniel Checketts, Eduardo Dunayevich, Volker Knappertz, (unknown) Hit paper breakdown →	2020	192
3	Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results Epilepsia ·Jerzy P. Szaflarski, E. Martina Bebin, Anne M. Comi, Anup D. Patel, Charuta Joshi, Daniel Checketts, Jules C. Beal, Linda Laux, Lisa M. De Boer, Matthew H. Wong, Merrick Lopez, Orrin Devinsky, Paul D. Lyons, Pilar Pichon Zentil, Robert Wechsler, (unknown)	2018	158
4	Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results Epilepsy Research ·Linda Laux, E. Martina Bebin, Daniel Checketts, Michael Chez, Robert Flamini, Eric D. Marsh, Ian Miller, Kathryn Nichol, Yong Park, Eric Segal, Laurie E. Seltzer, Jerzy P. Szaflarski, Elizabeth A. Thiele, Arie Weinstock	2019	143
5	Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study Epilepsia ·Elizabeth A. Thiele, Eric D. Marsh, Maria Mazurkiewicz‐Bełdzińska, Jonathan J. Halford, Boudewijn Gunning, Orrin Devinsky, Daniel Checketts, Claire Roberts	2019	103
6	A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma British Journal of Cancer ·(unknown), Chris Twelves, Michael Sabel, Daniel Checketts, Sharon A. Miller, Bola Tayo, Maria Jové, Lucy Brazil, Susan Short	2021	78
7	Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial Epilepsia ·Anup D. Patel, Maria Mazurkiewicz‐Bełdzińska, Richard Chin, António Gil‐Nagel, Boudewijn Gunning, Jonathan J. Halford, Wendy G. Mitchell, Μ. Scott Perry, Elizabeth A. Thiele, Arie Weinstock, Eduardo Dunayevich, Daniel Checketts, Orrin Devinsky	2021	74
8	Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial Epilepsia ·Ingrid E. Scheffer, Jonathan J. Halford, Ian Miller, Rima Nabbout, Rocío Sánchez‐Carpintero, Yael Shiloh‐Malawsky, Matthew H. Wong, Marta Żołnowska, Daniel Checketts, Eduardo Dunayevich, Orrin Devinsky	2021	60
9	Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials Acta Neurologica Scandinavica ·Orrin Devinsky, Elizabeth A. Thiele, Stephen Wright, Daniel Checketts, Gilmour Morrison, Eduardo Dunayevich, Volker Knappertz	2020	40
10	Abrupt withdrawal of cannabidiol (CBD): A randomized trial Epilepsy & Behavior ·Lesley Taylor, Julie C. Crockett, Bola Tayo, Daniel Checketts, Kenneth W. Sommerville	2020	37
11	Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials Acta Neurologica Scandinavica ·Boudewijn Gunning, Maria Mazurkiewicz‐Bełdzińska, Richard Chin, Hari Bhathal, Charlotte Nortvedt, Eduardo Dunayevich, Daniel Checketts	2020	32
12	Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials Epilepsia ·Michael Privitera, Hari Bhathal, Matthew H. Wong, J. Helen Cross, Elaine Wirrell, Eric D. Marsh, Maria Mazurkiewicz‐Bełdzińska, Vicente Villanueva, Daniel Checketts, Volker Knappertz, Kevan VanLandingham	2021	28
13	Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial Developmental Medicine & Child Neurology ·Charlie Fairhurst, Ram Kumar, Daniel Checketts, Bola Tayo, Susie Turner	2020	22
14	Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program Epilepsia ·Jerzy P. Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D. Park, Pilar Pichon Zentil, Anup D. Patel, Elizabeth A. Thiele, Robert Wechsler, Daniel Checketts, Farhad Sahebkar	2022	21
15	Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials Epilepsia ·Jennifer Madan Cohen, Daniel Checketts, Eduardo Dunayevich, Boudewijn Gunning, Ann Hyslop, Deepak Madhavan, Vicente Villanueva, Marta Żołnowska, Sameer M. Zuberi	2021	18
16	Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6 Epilepsia ·Joyce Y. Wu, Hannah R. Cock, Orrin Devinsky, Charuta Joshi, Ian Miller, Colin Roberts, Rocío Sánchez‐Carpintero, Daniel Checketts, Farhad Sahebkar	2022	16
17	Evaluation and Calibration of a Binocular Infrared Pupillometer for Measuring Relative Afferent Pupillary Defect Journal of Neuro-Ophthalmology ·Audrey Shwe-Tin, Guy T. Smith, Daniel Checketts, Ian Murdoch, Daniel R. Taylor	2012	16
18	Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials Multiple Sclerosis and Related Disorders ·Jacqueline A. Nicholas, Fred Lublin, Sylvia Klineova, Joris Berwaerts, Robert Chinnapongse, Daniel Checketts, Sajida Javaid, Joshua R. Steinerman	2023	10
19	Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events (AEs) in the Tuberous Sclerosis Complex (TSC) Phase 3 Randomized Controlled Trial (GWPCARE6) (674) Neurology ·Joyce Y. Wu, Hannah R. Cock, Orrin Devinsky, Charuta Joshi, Ian Miller, Colin Roberts, Rocío Sánchez‐Carpintero, Daniel Checketts, Farhad Sahebkar	2020	6
20	Long-term Efficacy and Safety of Cannabidiol (CBD) in Patients with Tuberous Sclerosis Complex (TSC): 4-year Results from the Expanded Access Program (EAP) (2405) Neurology ·Arie Weinstock, E. Martina Bebin, Daniel Checketts, Gary Clark, Jerzy P. Szaflarski, Laurie E. Seltzer, Elizabeth A. Thiele, Farhad Sahebkar	2021	6

About Daniel Checketts

Daniel Checketts is a scholar working on Pharmacology, Psychiatry and Mental health, Genetics, Clinical Biochemistry and Cellular and Molecular Neuroscience, having authored 29 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cannabis and Cannabinoid Research (21 papers), Epilepsy research and treatment (15 papers), Hemoglobinopathies and Related Disorders (6 papers), Metabolism and Genetic Disorders (4 papers), Pharmacological Effects and Toxicity Studies (4 papers), Neuroscience and Neuropharmacology Research (4 papers), Botulinum Toxin and Related Neurological Disorders (3 papers) and Polyomavirus and related diseases (2 papers). The work is most often cited by research in Pharmacology (1.2k citations), Psychiatry and Mental health (922 citations), Cellular and Molecular Neuroscience (560 citations), Pediatrics, Perinatology and Child Health (369 citations) and Toxicology (50 citations). Daniel Checketts has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Orrin Devinsky, Anup D. Patel, Claire Roberts, Vicente Villanueva, Michael Privitera, Elaine Wirrell, Kevan VanLandingham, J. Helen Cross, Sameer M. Zuberi and Sam M. Greenwood. Their work appears in journals such as Epilepsia, Neurology, Multiple Sclerosis and Related Disorders, Acta Neurologica Scandinavica and Epilepsy & Behavior.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact